Cita APA

Madoz-Gúrpide, J., Zazo, S., Chamizo, C., Casado, V., Caramés, C., Gavín, E., . . . Rojo, F. (2015). Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer.

Citación estilo Chicago

Madoz-Gúrpide, Juan, Sandra Zazo, Cristina Chamizo, Victoria Casado, Cristina Caramés, Eduardo Gavín, Ion Cristóbal, Jesús Miguel García-Foncillas López, y Federico Rojo. Activation of MET Pathway Predicts Poor Outcome to Cetuximab in Patients With Recurrent or Metastatic Head and Neck Cancer. 2015.

Cita MLA

Madoz-Gúrpide, Juan, et al. Activation of MET Pathway Predicts Poor Outcome to Cetuximab in Patients With Recurrent or Metastatic Head and Neck Cancer. 2015.